<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051450</url>
  </required_header>
  <id_info>
    <org_study_id>CRC_immune2018</org_study_id>
    <nct_id>NCT04051450</nct_id>
  </id_info>
  <brief_title>Immune Checkpoints in Colorectal Cancer</brief_title>
  <official_title>Immune Checkpoints in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) ranked the first in cancer incidence in Hong Kong and it is
      frequently lethal with heterogeneous drug responses and survival outcomes. Immune-based
      approaches targeting to enhance tumor-specific responses have been actively under
      investigation as therapeutic strategies. Currently, PD1 and PD-L1 blockade has shown
      promising results in clinical trials especially in colorectal cancer patients with
      microsatellite instability. This study aims to examine the role of PD-L1/PD1 in immune
      cell-mediated cytotoxicity in colorectal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To examine the role of PD-L1/PD1 in immune cell-mediated cytotoxicity in colorectal
      cancer patients.

      Objectives: 1. Comprehensive investigation of PD-L1/PD1 in colorectal cancer in association
      with chemotherapy responses and immune activities; 2. Examine the functional role of
      PD-L1/PD1 targeting in immune cell-mediated cytotoxicity.

      Hypothesis: It is hypothesized that PD-L1/PD1 has pivotal role on the immune cell-mediated
      cytotoxicity in colorectal cancer.

      Significances: The current study will elucidate the significance of PD-L1/PD1 on
      chemo-resistance and the effect on immune cells and their functional properties. The study
      will enhance the understanding on chemotherapy response and immune evasion. The long-term
      goal is to provide the crucial information on oncoimmunology to improve efficacy of
      immunotherapy in cancer treatment.

      Subjects: Only those patients for whom colorectal cancer is the indicated clinical diagnosis
      will be recruited in the current study. Possible participants will be patients undergoing
      tumor resection or endoscopic examination at the Department of Surgery, Prince of Wales
      Hospital, Shatin, Hong Kong. Specimens will be collected from sixty-eight colorectal cancer
      patients. The estimated duration for collection of all the necessary samples will be two
      years. With at least one year of follow-up information, the proposed study should be
      completed in three years. For the current study, single blood sample (10 ml of peripheral
      blood in EDTA) will be drawn before the operation or endoscopic session. A small portion of
      the tumor and non-tumor tissue tissues from resected specimens or biopsy tissues will be
      collected for histological evaluation, primary culture and for comparison of the genetic and
      protein components in the blood specimen.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Generation of candidate biomarker GEP by laboratory assay qPCR for prognostication.</measure>
    <time_frame>Three years.</time_frame>
    <description>Biomarker GEP will be investigated by laboratory assay real-time quantitative PCR. The biomarker levels in tissue specimens and the association with recurrence-free survival will be analyzed for prognostication.</description>
  </primary_outcome>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample (10ml peripheral blood) will be drawn before the operation or endoscopic
      session. A small portion of the tumor and non-tumor tissue tissues from resected specimens or
      biopsy tissues will be collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients undergoing resection or endoscopic examination at the Department
        of Surgery, Prince of Wales Hospital, Shatin, Hong Kong
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  colorectal cancer patients undergoing resection or endoscopic examination at the
             Department of Surgery, Prince of Wales Hospital, Shatin, Hong Kong

        Exclusion Criteria:

          -  patients who do not consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siu Tim Cheung, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wing Chi Ng</last_name>
    <phone>37636101</phone>
    <email>linda_nwc@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <contact>
      <last_name>Wing Chi Ng</last_name>
      <phone>37636101</phone>
      <email>linda_nwc@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016 May 5;14:73. doi: 10.1186/s12916-016-0623-5. Review.</citation>
    <PMID>27151159</PMID>
  </reference>
  <reference>
    <citation>Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017 Jun 21;18(6). pii: E1324. doi: 10.3390/ijms18061324. Review.</citation>
    <PMID>28635639</PMID>
  </reference>
  <reference>
    <citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490-1502. doi: 10.1016/S0140-6736(13)61649-9. Epub 2013 Nov 11. Review.</citation>
    <PMID>24225001</PMID>
  </reference>
  <reference>
    <citation>Guinney J, Dienstmann R, Wang X, de Reyni√®s A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.</citation>
    <PMID>26457759</PMID>
  </reference>
  <reference>
    <citation>Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015 Jan;5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863. Epub 2014 Oct 30.</citation>
    <PMID>25358689</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CHEUNG, Siu Tim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

